Benefits of PGx Testing

At ACLS Pharmacogenomics Laboratory, DNA tests are used to determine a person’s response to specific medications from his or her genetic profile. Pharmacogenomics (PGx) will find a drug’s effectiveness or toxicity associated with genetic variation. These tests are referred to as “personalized” or “precision” medicine, because they find drug and drug combinations ideal for each individual’s distinctive genetic makeup. PGx can be used in virtually all specialties: cardiology, oncology, mental health, allergy, pain management, and more. Drug metabolism is linked to genotypes, and the association helps all types of clinicians find the best treatment program and medication dose.

While always a highly-researched field, PGs has been most utilized in recent years. Clinical trials have benefited from the tests to prevent ADRs, decrease negative side effects and provide better cost-efficiency.

The FDA advocates clinical pharmacogenomics because of its potential to increase efficacy and safety.

Major benefits of performing PGx testing include:

  • Select optimal therapy & reduce “trial-and-error” medicine
  • Improve the selection of drug targets
  • Increase patient compliance with therapy
  • Shift the emphasis in medicine from reaction to prevention
  • Reduce the overall cost of Healthcare
  • Provide a potential explanation to the compliant patient for ineffective/harmful drugs
  • Forensics (overdoses)

PGx can also be used as a prospective screening tool

  • Carried out in the absence of a pre-existing medical condition
  • Used to identify potential future problems, hopefully preventing them from occurring
  • Screening family members of patients known to have had an ADR

Major areas that would benefit from PGx testing include:

  • Psychiatry – antidepressants, antipsychotics
  • Anticoagulation therapy – warfarin, plavix
  • Transplant – azathioprine
  • Oncology – tamoxifen, chemotherapeutic drugs
  • Drug addiction – nicotine
  • Pain management – opioid analgesics
  • Cardiology – beta-blockers

ACLS currently offers 55 clinically actionable pharmacogenetic markers to help physicians target treatment and medications based on each patient’s genetics.  Studies have shown that incorporating genetic factors into the prescribing process can help improve efficacy and reduce adverse effects.  Tests can be ordered as a panel, or individually. Our customized panel of PGx testing consists of 55 markers that cover 12 genes and since it’s customized, it can be changed depending on the particular requirements at that time.

Current ACLS Panels

  • ACLS Pain Panel (CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, CYP2B6, COMT, CYP1A2 and OPRM1)
  • ACLS Psychotropic (CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5, CYP1A2, COMT and ANKK1/DRD2)
  • ACLS Cardiovascular (CYP2D6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, VKORC1, F2/Factor II, F5/Factor V Leiden, MTHFR, and SLCO1B1)

ACLS laboratory is fully accredited and consistently maintains the highest standards. We are CLIA-certified and licensed to perform testing in all U.S. states and Puerto Rico.

PGx testing is the foundation of personalized medicine and it will help us select the right drug at the right dose, for the right patient. ACLS PGx testing is the foundation of personalized medicine and it will help us select the right drug at the right dose, for the right patient.